AUS
NZ
UK
CA
USA
IND
Highlights
- Pro Medicus (ASX:PME) secures a long-term contract valued at $33 million.
- Visage 7 Enterprise Imaging Platform to be implemented at University of Kentucky.
- Company’s North American market expansion continues with strategic partnerships.
Medical imaging technology company, Pro Medicus (ASX:PME), has recently entered into a major long-term agreement with the University of Kentucky, marking a significant milestone in its strategic expansion into North American academic institutions. The deal, valued at $33 million, is set to strengthen Pro Medicus' footprint in the region, showcasing the growing demand for its advanced imaging solutions.
The partnership, which spans nine years, involves the deployment of Pro Medicus' flagship cloud-based product, the Visage 7 Enterprise Imaging Platform. Through this transaction, Pro Medicus will provide the University of Kentucky with a unified diagnostic imaging system that integrates seamlessly across the university’s medical network. Expected to go live in the second quarter of 2025, the platform will serve as a key component in enhancing diagnostic capabilities and improving medical imaging services for the institution.
The contract also positions Pro Medicus to continue its expansion within the North American healthcare sector. The company has already secured similar contracts in the United States with leading academic and healthcare institutions like Duke University and Trinity Health, reinforcing its reputation as a provider of cutting-edge imaging solutions. This ongoing trend aligns with Pro Medicus' robust growth trajectory, further expanding its global presence.
For Pro Medicus, the University of Kentucky deal is part of a broader strategy to expand its North American customer base. CEO Dr. Sam Hupert shared his optimism regarding the deal’s potential, stating, “Our pipeline remains strong and spans all market segments. As has been the case with many of our recent contracts, this deal is for our full stack comprising all three Visage products, a trend we see continuing.”
In the financial markets, this exciting news has spurred confidence in Pro Medicus’ stock. Shares of Pro Medicus, which have already more than doubled over the past year, saw an immediate 2.5% increase, reaching $260 in early trading on the ASX. With the company’s portfolio of contracts in place, this momentum shows no signs of slowing.
Pro Medicus is a Melbourne-based company that specializes in medical imaging software and services, catering to hospitals, healthcare providers, and imaging centres worldwide. As the demand for sophisticated medical imaging technology rises, Pro Medicus continues to lead in the development of transformative solutions that enhance healthcare quality and efficiency.
Looking ahead, this landmark deal further strengthens Pro Medicus’ position as a global leader in medical imaging technology. With a solid pipeline of future opportunities and expanding client base, the company is poised to continue its growth in the international healthcare market.
